Clinical trials: Clinical Benefit Rate
Progression-free Survival, Overall Survival
Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades.
- Conditions
- Progression-free Survival, Overall Survival, Clinical Benefit Rate, Toxicity
- Trial name
- APFAO (NCT03359018)
- Testing
- Apatinib, SHR-1210
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Peking University People's Hospital
Infertility of Uterine Origin
Clinical Study of PGT-A Versus PGT-A+ERA
Patients who have shown previous implantation failures, despite transferring good quality and chromosomally normal embryos (diagnosed by PGT-A), could have a displaced Window of Implantation (WOI) and consequently, alterations in…
- Trial name
- PGT-A&ERA (NCT03530254)
- Testing
- PGT-A, ERA Test
- Where
- 15 sites in United States, Argentina and 10 more
- Volunteers
- 368 people
- Sponsor
- Igenomix